OUTLOOK THERAPEUTICS

OUTLOOK THERAPEUTICS

Yahoo Finance • last month

Oncobiologics Q3 Earnings Call Highlights

Key Points Interested in Oncobiologics, Inc.? Here are five stocks we like better. FDA approval clears the way for LYTENAVA's U.S. launch later this year as the only FDA-approved ophthalmic bevacizumab formulation for wet AMD. Management... Full story

Yahoo Finance • 2 months ago

Earnings Week Ahead: SMCI, CSCO, JD, PLUG, and more

[Business Person Reviewing Quarterly Report During Meeting in Office Setting] The second full week of August features a diverse earnings slate spanning AI infrastructure, semiconductors, space technology, healthcare, financials, and consu... Full story

Yahoo Finance • 2 months ago

Outlook gains approval for ophthalmic bevacizumab for wet AMD

[AMD Abbreviation or acronym of age-related macular degeneration - eye problem in older persons. Word AMD is on foreground near eye model with stethoscope and visual acuity test on blurry background] Shidlovski * The US FDA has approved... Full story

Yahoo Finance • 2 months ago

Top Biotech Gainers: NXTC Soars On Merger Deal, BMGL Moves Past Nasdaq Woes, OTLK Awaits FDA Verdict

(RTTNews) - Today's top gainers in the biotech space include NextCure, ahead of its planned merger with a private company that will create a newly branded public entity; Basel Medical, which recently regained Nasdaq compliance; and Outlook... Full story

Yahoo Finance • 4 months ago

Outlook Therapeutics Wins FDA Appeal For NAMD Therapy; Stock Up

(RTTNews) - Outlook Therapeutics Inc. (OTLK) announced that the U.S. FDA has granted its appeal following completion of the Formal Dispute Resolution process for ONS-5010/LYTENAVA (bevacizumab-vikg). Its investigational therapy for neovasc... Full story

Yahoo Finance • 5 months ago

Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment... Full story

Yahoo Finance • 5 months ago

Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

ISELIN, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that... Full story

Yahoo Finance • 6 months ago

FDA Accepts Outlook Therapeutics' FDRR To Resolve ONS-5010/LYTENAVA Regulatory Issues; Stock Up

(RTTNews) - Outlook Therapeutics, Inc. (OTLK), a clinical-stage biotechnology company, announced on Tuesday that the U.S. Food and Drug Administration FDA has accepted its Formal Dispute Resolution Request or FDRR and has granted a meeting... Full story

Yahoo Finance • 7 months ago

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an upd... Full story

Yahoo Finance • 7 months ago

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026Additional European launches expected in 2026Type A meeting request submitted to the U.S. Food and Drug Administ... Full story

Yahoo Finance • 9 months ago

Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images * The US FDA has issued a Complete Response Letter to Outlook Therapeutics (OTLK [https://seekingalpha.com/symbol/OTLK]) for its r... Full story

Yahoo Finance • 9 months ago

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

ISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that t... Full story

Yahoo Finance • 10 months ago

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that B... Full story

Yahoo Finance • 10 months ago

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for b... Full story

Yahoo Finance • 11 months ago

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced it ha... Full story

Yahoo Finance • 12 months ago

Outlook Therapeutics Provides Update on Type A Meeting with FDA

ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that... Full story

Yahoo Finance • last year

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that... Full story

Yahoo Finance • last year

Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 0.2% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last year

Outlook Therapeutics Requests Type A Meeting with FDA

ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that... Full story

Yahoo Finance • last year

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

First commercial sales of LYTENAVA™ (bevacizumab gamma) achieved in EuropeONS-5010/LYTENAVA™ (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, in the United States ISELIN, N.J., Aug. 14, 2025 (GLOBE... Full story